期刊
ONCOIMMUNOLOGY
卷 3, 期 1, 页码 -出版社
LANDES BIOSCIENCE
DOI: 10.4161/onci.27296
关键词
adaptive immunity; CD4; CD40; CD40L; CD8; HER2; Herceptin; antibody; immunotherapy; neu
资金
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007090] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA141975, P01 CA097296] Funding Source: Medline
- NIAID NIH HHS [T32 AI007090] Funding Source: Medline
Preclinical studies have established that CD8(+) T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4(+) T cells and CD40/CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据